Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Gastroenterologist Dr Salhab warns that liver cirrhosis can lead to overt hepatic encephalopathy, impacting brain function ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

Cirrhosis or fibrosis of the liver can occur due to several liver-related diseases and conditions, such as hepatitis, non-alcoholic fatty liver disease, and excessive alcohol consumption.

New research in JAMA Internal Medicine has challenged the current guideline recommending 5-7 days of preventive antibiotics ...

Cirrhosis is also associated with an enlarged spleen that may entrap platelets, the blood cells involved in clotting; so measuring a person's platelet count can be useful in diagnosing the liver ...